By analyzing Foghorn Therapeutics' earnings estimates, investors can diagnose different trends across Foghorn Therapeutics' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Foghorn Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.
Covid
Foghorn Therapeutics is projected to generate -0.65 in earnings per share on the 30th of June 2024. Foghorn Therapeutics earnings estimates module stress-tests analyst consensus about projected Foghorn Therapeutics EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Many public companies, such as Foghorn Therapeutics, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Foghorn Therapeutics' earnings estimates, investors can diagnose different trends across Foghorn Therapeutics' analyst sentiment over time as well as compare current estimates against different timeframes. At this time, Foghorn Therapeutics' Gross Profit is fairly stable compared to the past year. Gross Profit Margin is likely to rise to 0.78 in 2024, whereas Pretax Profit Margin is likely to drop (2.90) in 2024.
Foghorn
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Foghorn Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Foghorn Therapeutics Earnings per Share Projection vs Actual
About Foghorn Therapeutics Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Foghorn Therapeutics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Foghorn Therapeutics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Foghorn Therapeutics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.